Category Archives: TSR-011 from Tesaro

List of drugs in clinical trials

List of 10 ALK inhibitor drugs currently (or soon to be) in clinical trials: Ariad AP26113 Astellas ASP-3026 Chugai Alectinib (filed NDA in Japan) Nerviano NMS-E628. (Licensed by Ignyta and renamed RXDX-101) Novartis LDK-378 Pfizer Crizotinib (FDA approved but several … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, brigatinib-Alunbrig from Takeda, CEP-37440, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, NMS-E628, Potential Treatments, Research, RXDX-101 - entrectinib - by Ignyta, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

Tesaro update from ESMO

— TSR-011 Identified as a Potent Dual Inhibitor of ALK and TRK Kinases — Preliminary Clinical Activity Demonstrated in Patients with Several Tumors, Including ALK-Positive NSCLC Patients Previously Treated with Crizotinib — Phase 2 Dose Selection and Cohort Expansion Into … Continue reading

Posted in Lung cancer, Potential Treatments, Research, Side Effects, TSR-011 from Tesaro | Leave a comment

Tesaro clinical trial

Tesaro has sent out a press release Oct. 2, 2012 announcing that their Investagational Drug Application for TSR-011 has been approved. As of Nov. 1, 2012, Tesaro sent out a press release stating the clinical trial for TSR-011 had started … Continue reading

Posted in Potential Treatments, TSR-011 from Tesaro | 1 Comment